ECP 2019 Final Programme

Sunday, 8 Sept 180 ECP 2019 · Nice Breakfast and Luncheon Industry Symposia e Sunday, 8 September 2019 LS-01 Industry Symposium 13:00–14:30 Apollon Biomarkers in immuno-oncology: perspectives from the pathologist & oncologist (BMS) Chair: Frederique Penault-Llorca, France 001 13:00–13:30 The I-O evolution: drawing from the past to shape the future Frederique Penault-Llorca, France 002 13:30–14:00 Choosing the right treatment at the right time: insights into the patient journey Josep M. Piulats, Spain 003 14:00–14:30 Technical considerations for biomarker testing: what's now, what's next? Chris Abbosh, United Kingdom LS-05 Industry Symposium 13:00–14:30 Athéna Advances in breast cancer care: exciting prospects in triple negative breast cancer and personalised cancer immunotherapy (Roche) Chairs: Tibor Tot, Sweden Anna Sapino, Italy 001 13:00–13:10 Welcome & introduction Anna Sapino, Italy Tibor Tot, Sweden 002 13:10–13:30 Recent advances in breast cancer manage- ment: how clinician will need more diagnosis Filippo Montemurro, Italy 003 13:30–13:50 Importance & challenges of triple negative breast cancer diagnosis Sahin Aysegul, USA 004 13:50–14:10 PD L1 as companion diagnosis in metastatic triple negative breast cancer Magali Lacroix Triki, France 005 14:10–14:30 Discussion & Q&A Tibor Tot, Sweden LS-02 Industry Symposium 13:00–14:30 Uranie/Calliope BRCA testing to guide precision medicine: strengthening the foundations and building for the future (MSD & AstraZeneca) Chair: Reinhard Büttner, Germany 001 13:00–13:05 Welcome and introduction Reinhard Büttner, Germany 002 13:05–13:25 Optimising patient selection in ovarian cancer: the rationale for tumour BRCA testing Reinhard Büttner, Germany 003 13:25–13:45 The keys to quality in tumour BRCA testing Marjolijn Ligtenberg, The Netherlands 004 13:45–14:05 BRCA testing in precision medicine beyond ovarian cancer Michael Pishvaian, USA 005 14:05–14:30 Q&A/Closing Remarks Reinhard Büttner, Germany LS-03 Industry Symposium 13:00–14:30 Hermès Are you prepared for routine tumour mutation burden (TMB) analysis in NSCLC? (AstraZeneca) Chair: Paul Hofman, France 001 13:00–13:05 Welcome & introduction Paul Hofman, France 002 13:05–13:25 Predicting response to immunotherapy by measuring TMB using tissue or liquid biopsies Lea Payen, France